Drug updated on 11/15/2023
| Dosage Form | Film-coated tablet (oral; 20 mg, 40 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs).
- For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Scemblix (asciminib) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Scemblix. | 2022 | EMA |
| Clinical and pharmacoeconomic combined report: asciminib (Scemblix). | 2022 | CADTH |